Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGenix Technologies Inc (RTGN) specializes in advanced retinal imaging systems designed to transform ocular health screening through noninvasive technology. This page serves as the definitive source for official announcements, financial disclosures, and progress updates related to their high-resolution imaging platforms and genetic research initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and analyses of RTGN's role in telemedicine-enabled eye care solutions.
Key content areas cover device approvals, research collaborations, financial performance, and technology enhancements. All materials are sourced from verified corporate communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to RetinalGenix's latest developments in medical imaging innovation and their expanding impact on accessible eye care solutions across clinical settings.
RetinalGenix Technologies (OTCQB:RTGN) has secured a laboratory lease agreement with MBC BioLabs in San Carlos, California. The agreement includes a potential investment option from Mission BioCapital, MBC Biolabs' affiliate. The facility will be used to advance the company's DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform and research on repurposing existing drugs for dementia, parkinsonism, and macular degeneration.
The fully equipped laboratory provides access to advanced scientific equipment and is strategically located near Charles River Laboratories' vivarium facility. Dr. Fred Chasalow, Special Consultant for Therapeutics, will lead the laboratory activities. The company is also in discussions for potential collaboration with Dr. Anatoly Dritschilo of Shuttle Pharmaceuticals and plans to expand IRB approval for clinical studies across multiple practices.
RetinalGenix Technologies (OTCQB:RTGN) announced its participation in the 37th Annual Roth Conference from March 16th to 18th, 2025, at The Laguna Cliffs Marriott in Dana Point, CA.
The company will showcase its RetinalCam™, a proprietary high-resolution, real-time retinal and ocular imaging system currently in the prototype stage and actively imaging patients. This technology aims to detect early biomarkers that could prevent potential blindness or systemic disease. RetinalGenix projects to complete testing by Q2 2025, with initial device sales expected later that year.
Additionally, the company is developing its DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software for validating and guiding novel therapeutic product development. CEO Jerry Katzman, MD, will be available for one-on-one meetings on March 17th and 18th during the conference, which is recognized as one of the premier investor events in the U.S.
RetinalGenix Technologies (OTCQB:RTGN) has achieved a milestone in developing its high-resolution retinal imaging device and remote monitoring system, successfully imaging patients with its first prototype using both near-infrared and green modes. The device enables secure, real-time 24/7 remote monitoring without requiring pupil dilation or technicians for a 40° field of vision.
The company plans to install units in various healthcare settings and public locations. A specialized network of retinal specialists will be available to review images remotely. The system is designed as a screening tool, not for diagnostic purposes, facilitating immediate resolution through physical examination or prompt doctor visits.
RetinalGenix is also conducting an IRB-approved investigation to correlate genetic markers with intraocular injection success rates for macular degeneration treatment. The company aims to develop a pharmaco-genetic test costing approximately $355 to predict treatment effectiveness. Additionally, RetinalGenix has filed patents in the US and Europe for repurposed FDA-approved pharmaceuticals targeting Dry AMD, diabetic retinopathy, and dementia.
FAQ
What is the current stock price of RETINALGENIX TECHNOLOGIES (RTGN)?
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
